{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T07:25:33Z","timestamp":1780471533677,"version":"3.54.1"},"reference-count":18,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2012,8,27]],"date-time":"2012-08-27T00:00:00Z","timestamp":1346025600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arthritis Care &amp; Research"],"published-print":{"date-parts":[[2012,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>To estimate the relative risk of incident cancer diagnosis among patients with juvenile idiopathic arthritis (JIA) compared to patients without JIA.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A cohort of biologics\u2010naive patients diagnosed with JIA between 1998 and 2007 and a matched cohort of comparators without JIA were assembled from the PharMetrics Patient\u2010Centric Database. The primary outcome was any incident malignancy, excluding nonmelanoma skin cancer and carcinoma in situ. Claims profiles of patients with any cancer\u2010related diagnosis codes were reviewed to determine outcomes. Incidence rates and 95% confidence intervals (95% CIs) of cancer were calculated and compared between cohorts using Cox proportional hazards regression. Standardized incidence ratios (SIRs) for each cohort compared to the general population were calculated using reference rates from the US Surveillance, Epidemiology, and End\u2010Results (SEER) program.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The JIA and non\u2010JIA cohorts included 3,605 and 37,689 patients, respectively, with a mean age of 11 years. The incidence rates of cancer were 67.0 (95% CI 1.3\u2013132.5) cases\/100,000 person\u2010years (PY) for JIA and 23.2 (95% CI 12.2\u201334.2) cases\/100,000 PY for non\u2010JIA. The risk of cancer associated with biologics\u2010naive JIA was elevated (hazard ratio 2.8, 95% CI 0.9\u20138.3). The JIA cohort had a significantly elevated SIR of 4.0 (95% CI 2.6\u20136.0); the non\u2010JIA cohort SIR was not significantly above SEER rates (SIR 1.4, 95% CI 0.6\u20132.6).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>We found a nearly 3\u2010fold increased risk of cancer in biologics\u2010naive JIA patients, which approached significance despite the small number of outcomes. This finding suggests an elevated underlying risk of cancer in this disease population.<\/jats:p><\/jats:sec>","DOI":"10.1002\/acr.21709","type":"journal-article","created":{"date-parts":[[2012,4,17]],"date-time":"2012-04-17T12:41:14Z","timestamp":1334666474000},"page":"1357-1364","source":"Crossref","is-referenced-by-count":61,"title":["Risk of malignancy in children with juvenile idiopathic arthritis not treated with biologic agents"],"prefix":"10.1002","volume":"64","author":[{"given":"Beth L.","family":"Nordstrom","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Mines","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Mercaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Aquino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie J.","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,8,27]]},"reference":[{"key":"e_1_2_8_2_2","first-page":"1520","article-title":"Worldwide prevalence of juvenile arthritis: why does it vary so much?","volume":"29","author":"Manners PJ","year":"2002","journal-title":"J Rheumatol"},{"key":"e_1_2_8_3_2","first-page":"390","article-title":"International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001","volume":"31","author":"Petty RE","year":"2004","journal-title":"J Rheumatol"},{"key":"e_1_2_8_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20460"},{"key":"e_1_2_8_5_2","doi-asserted-by":"publisher","DOI":"10.1186\/ar2404"},{"key":"e_1_2_8_6_2","unstructured":"Food and Drug Administration. Early communication about an ongoing safety review of tumor necrosis factor (TNF) blockers (marketed as Remicade Enbrel Humira and Cimzia). URL:http:\/\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/DrugSafetyInformationforHeathcareProfessionals\/ucm070725.htm."},{"key":"e_1_2_8_7_2","unstructured":"Food and Drug Administration. Follow\u2010up to the June 4 2008 early communication about the ongoing safety review of tumor necrosis factor (TNF) blockers (marketed as Remicade Enbrel Humira Cimzia and Simponi).http:\/\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/DrugSafetyInformationforHeathcareProfessionals\/ucm174449.htm?utm_campaign=Google2&utm_source=fdaSearch&utm_medium=website&utm_term=follow\u2010uptothejune4 2008early&utm_content=1."},{"key":"e_1_2_8_8_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.087593"},{"key":"e_1_2_8_9_2","doi-asserted-by":"publisher","DOI":"10.1186\/1546-0096-8-18"},{"key":"e_1_2_8_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.27511"},{"key":"e_1_2_8_11_2","first-page":"S188","article-title":"Inflammatory activity, but not methotrexate or prednisone use predicts non\u2010Hodgkin's lymphoma in rheumatoid arthritis: a 25\u2010year study of 1,767 RA patients","volume":"41","author":"Wolfe F","year":"1998","journal-title":"Arthritis Rheum"},{"key":"e_1_2_8_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.21675"},{"key":"e_1_2_8_13_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.033241"},{"key":"e_1_2_8_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.27741"},{"key":"e_1_2_8_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/0959-8049(96)00210-9"},{"key":"e_1_2_8_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0215(20001101)88:3<497::AID-IJC27>3.0.CO;2-J"},{"key":"e_1_2_8_17_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0706290"},{"key":"e_1_2_8_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keq292"},{"key":"e_1_2_8_19_2","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/1546-0096-8-24","article-title":"The effect of infliximab plus methotrexate on the modulation of inflammatory disease markers in juvenile idiopathic arthritis: analyses from a randomized, placebo\u2010controlled trial","volume":"8","author":"Visvanathan S","year":"2010","journal-title":"Pediatr Rheumatol Online J"}],"container-title":["Arthritis Care &amp; Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Facr.21709","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/acr.21709","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T15:17:32Z","timestamp":1759418252000},"score":1,"resource":{"primary":{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/10.1002\/acr.21709"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8,27]]},"references-count":18,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["10.1002\/acr.21709"],"URL":"https:\/\/doi.org\/10.1002\/acr.21709","archive":["Portico"],"relation":{},"ISSN":["2151-464X","2151-4658"],"issn-type":[{"value":"2151-464X","type":"print"},{"value":"2151-4658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,8,27]]}}}